エンハーツ、HER2陽性早期乳がんの術後療法で米国FDAの優先審査に指定 再発・死亡リスクを53％低減 | STELLANEWS.LIFE STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見 | STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見

【ENHERTU Granted Priority Review in the US for Patients with HER2-Positive Early Breast Cancer】
エンハーツ、HER2陽性早期乳がんの術後療法で米国FDAの優先審査に指定 再発・死亡リスクを53％低減

stellanews.life/technology/9...

#Enhertu #BreastCancer #FDA #PriorityReview #HER2Positive #MedicalNews

China impulsa la innovación en oncología.
📊 Descubre en este póster 5 medicamentos innovadores para el cáncer de mama.

#CáncerDeMama #Dalpiciclib #Pyrotinib #Chidamide #Envafolimab #DisitamabVedotin #HER2 #HER2Positive #TargetedTherapy #ADC #TerapiasInnovadoras #DengYueMedicinasEnHongKong

Synapse: Your Connection to our MSK Authors
Meet: Mithat Gonen
Research Focus: Biostat/Epidemiology; Attending

Evaluating post-T-DXd treatment strategies in HER2-positive metastatic breast cancer
synapse.mskcc.org/synapse/work...

#HER2Positive #MetastaticBreastCancer
#TDXd #BreastCancerResearch

EU starts review of first-line Enhertu for breast cancer EMA starts its review of first-line Enhertu in HER2+ breast cancer, which could dramatically increase the eligible patient population for the drug.

The #EMA has started its review of #DaiichiSankyo and #AstraZeneca's #Enhertu as a first-line therapy for #HER2positive #breastcancer, setting up a possible approval later this year.

#TrastuzumabEmtansine achieved a 47.2% response rate with manageable safety in #HER2positive #MetastaticBreastCancer after pyrotinib/trastuzumab+pertuzumab failure, identifying potential #biomarkers through #SingleCellRNASequencing.

#OpenAccess in #STTT: doi.org/10.1038/s413...

🚨 HER2+ MBC Maintenance News! 🚨
The Phase 3 HER2CLIMB-05 trial (Dieras et al.) was simultaneously published at #SABCS25. This study assesses Tucatinib vs. Placebo with Trastuzumab/Pertuzumab as first-line maintenance.
👉 See the results: ascopubs.org/doi/abs/10.1...

#HER2Positive #BreastCancer

Nicole, who lives with HER2+ Metastatic Breast Cancer, shares her first-hand experience as a patient expert supporting the Enhertu submission.

📲 Link in bio to learn more about advocacy and how to get involved.

#METUPUK #PatientAdvocacy
#LivingWithMBC #HER2Positive #Enhertu

Combining the #BispecificAntibodies KN026 and KN046 delivers promising efficacy and manageable safety in advanced #HER2positive nonbreast #tumors, achieving high response rates—including 78.9% in first-line HER2-positive #GastricCancer.

#OpenAccess in #STTT: doi.org/10.1038/s413...

Major advances in treatment and care have led to improved survival for many women with advanced breast cancer, new study finds.

youtu.be/nJWKKsdFvYw

#MetastaticBreastCancer #AdvancedBreastCancer #BreastCancerSurvival #HER2Positive #HormoneReceptorPositive #TripleNegativeBreastCancer

Synapse: Your Connection to our MSK Authors
Meet: Richard M Steingart
Research Focus: Medicine; NE Emeritus

Cardiac safety of reduced cardiotoxicity surveillance during HER2-targeted therapy
synapse.mskcc.org/synapse/work...

#HER2Positive #BreastCancerResearch #Cardiotoxicity #CardioOncology

Current Treatment Approaches in HER2+ Metastatic Breast Cancer Panelists discussed how evolving strategies in HER2-positive metastatic breast cancer are shifting toward more personalized maintenance approaches, including the integration of CDK4/6 inhibitors and e...

Navigating HER2+ breast cancer? Experts break down how to choose the right patients and sequence treatments for HER2+ metastatic disease. Get the latest insights. #BreastCancer #HER2Positive #Oncology #TCSC

www.cancernetwork.com/view/current...

🚨 Late-breaking from #ASCO25: Dr. Kohei Shitara presents LBA4002 – DESTINY-Gastric04! T-DXd challenges RAM+PTX in 2L HER2+ metastatic #gastriccancer & GEJA 🔬 Will this redefine the standard of care? ow.ly/bpNQ50W2SFk

#HER2Positive #ASCO2025

Real-world data show that #Tucatinib + trastuzumab + capecitabine offers clinical benefit in heavily pretreated HER2+ metastatic #BreastCancer, even after T-DXd. Observations support the use of tucatinib-based therapy in later treatment lines.
#HER2Positive #Oncology #RealWorldEvidence

Managing Brain Metastases in HER2+  Breast Cancer: Second-Line Treatment Decisions Panelists discuss how the presence of brain metastases influences treatment decisions in HER2-positive (HER2+) breast cancer, highlighting the DESTINY-Breast12 trial demonstrating trastuzumab deruxtec...

Navigating treatment sequencing in HER2+ metastatic breast cancer is critical; especially when brain mets are involved. Second-line decisions change everything. Stay evidence-based. #TCSC #BreastCancer #HER2Positive #Oncology #CancerCare #BrainMetastase

www.onclive.com/view/managin...

Any advice on continuing to use a #coldcap despite losing clumps of hair please? #breastcancer #Her2positive #grade3 #hairloss

Not commonly seen without a clinical mass!
#PagetsDisease of nipple with associated invasion. Also #HGDCIS in subareolar ducts. Usually #ERNegative & #Her2Positive.
#pathsky
#Pathology
#BreastPath
😉

The Japanese phase III PRECIOUS study reveals that pertuzumab retreatment in combination with trastuzumab & chemotherapy significantly improves overall survival in patients with HER2-positive, locally advanced/metastatic breast cancer. #HER2Positive ascopost.com/news/februar...

EA1211/DIRECT aims to help doctors make better (more personalized) decisions around treatment for #patients with #HER2positive #BreastCancer. Consider learning more about this phase 2 #clinicaltrial if you have HER2-positive breast cancer. For more info: bit.ly/EA1211

How Combining Drugs May Be More Effective at Treating HER2-Positive Breast Cancer Elena Shagisultanova, MD, PhD, is working to uncover effective treatments for HER2-positive breast cancer patients by combining different drugs.

Fighting HER2-positive breast cancer: Dr. Elena Shagisultanova is breaking new ground with a triple-block approach to outsmart this resilient cancer. Cutting-edge research is paving the way for better treatments. 🌟 #HER2Positive #BreastCancerResearch #MedSky
https://buff.ly/3CQbL8n

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene - PubMed The HER-2/neu oncogene is a member of the erbB-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor. This gene has been shown to be amplified in human breas...

Understanding HER2 in Breast Cancer:

Slamon et al.'s 1987 study on HER2/neu amplification paved the way for targeted therapies like Herceptin. #HER2Positive #BreastCancer

pubmed.ncbi.nlm.nih.gov/3798106/

🚨 Open Letter to Regence BlueCross BlueShield of Utah 🚨

I’m sharing this letter publicly to shed light on a critical issue affecting my wife, Raven, who is battling HER2-positive breast cancer.

#breastcancer #her2positive #HealthcareJustice #cancertreatment #InsuranceReform #standardsofcare

line art done in the style of medieval woodblock printing depicting a woman in bed checking on her chest with a displeased look on her face, being watched over by an angelic bull

checking to make sure my boobs haven’t abandoned me just yet #breastcancer #her2positive